Industry
Medical - Diagnostics & Research
Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Loading...
Open
239.78
Mkt cap
20B
Volume
850K
High
243.78
P/E Ratio
46.08
52-wk high
243.78
Low
238.12
Div yield
0.01
52-wk low
191.97
Portfolio Pulse from Happy Mohamed
July 24, 2023 | 12:16 pm
Portfolio Pulse from Benzinga Newsdesk
July 11, 2023 | 11:27 am
Portfolio Pulse from Benzinga Insights
July 04, 2023 | 5:37 pm
Portfolio Pulse from Benzinga Insights
July 04, 2023 | 1:12 pm
Portfolio Pulse from Benzinga Insights
July 03, 2023 | 5:38 pm
Portfolio Pulse from Benzinga Insights
July 03, 2023 | 1:12 pm
Portfolio Pulse from Vandana Singh
June 08, 2023 | 6:00 pm
Portfolio Pulse from Benzinga Insights
June 05, 2023 | 1:02 pm
Portfolio Pulse from richadhand@benzinga.com
June 05, 2023 | 11:50 am
Portfolio Pulse from Benzinga Newsdesk
May 31, 2023 | 8:42 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.